Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Summary: Current evidence suggests GLP-1 receptor agonists are not associated with increased breast cancer risk, though decisions should be individualised with multidisciplinary input
Reviews Dis
MDL 3094 In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation has 346 litigants as of August 2023, an increase of 235 active cases over the past month, which is an over 200% jump in a single month
[24:05] A And I'm like, exactly
US$ 29.09
US$ 28.73
US$ 25.53
US$ 20.97
US$ 26.76
US$ 23.19
